Multicenter observational prospective study of nivolumab (Nivo) as 2+ line treatment in advanced refractory NSCLC pts: Clinical and quality of life outcomes.

Rashida Orlova,K. K. Laktionov,Larisa Bolotina,V V Breder,Anastasia Danilova,Elena Filippova,Anna Kornietskaya,Mikhail M. Kramchaninov,Eugenia K Kushniruk,Latipova Dh,Evgeny Ledin,Anastasia Mochalova,Fedor Vladimirovich Moiseenko,Tatiana Nikitina,Sergey Orlov,Svetlana Protsenko,K. A. Sarantseva,Daniil Stroyakovskiy,Anna V. Zinkovskaya,Tatyana Ionova

Multicenter observational prospective study of nivolumab (Nivo) as 2+ line treatment in advanced refractory NSCLC pts: Clinical and quality of life outcomes.

2019

e20567Background: We aimed to evaluate clinical and quality of life (QoL) outcomes of Nivo as 2+ line treatment in NSCLC pts within expanded access program and real world practice. Methods: Adult p...

Keywords:

Refractory
Prospective cohort study
Observational study
Nivolumab
Physical therapy
Oncology
Quality of life
Medicine
Internal medicine
Expanded access

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations